구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Panitumumab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Head and Neck Squamous Cell Carcinoma |
Overview Indication | Colorectal Cancer; Resectable Colorectal Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | Targeting the Epidermal Growth Factor Receptor Pathway |
MoA Biomarker | EGFR-positive malignancies, high |
PK/PD Half-life | 7.5 h |
PK/PD Species | Mouse, The primary endpoint was safety |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, The primary endpoint was safety |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Safety signal | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Selected reported efficacy | ORR 63.64% |
Clinical Reported ORR | 63.64% |
Clinical Result source | ClinicalTrials.gov NCT00819780 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00819780 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Panitumumab |
Overview Company | Amgen |
Overview Modality | ANTIBODY |
Overview Target | Head and Neck Squamous Cell Carcinoma |
Overview Indication | Colorectal Cancer; Resectable Colorectal Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | Targeting the Epidermal Growth Factor Receptor Pathway |
MoA Biomarker | EGFR-positive malignancies, high |
PK/PD Half-life | 7.5 h |
PK/PD Species | Mouse, The primary endpoint was safety |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, The primary endpoint was safety |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Safety signal | Safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer in the CodeBreaK 101 phase Ib study.. In the phase III CodeBreaK 300 trial (NCT05198934), the combination of sotorasib, a KRAS G12C inhibitor, and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (m… |
Clinical Selected reported efficacy | ORR 63.64% |
Clinical Reported ORR | 63.64% |
Clinical Result source | ClinicalTrials.gov NCT00819780 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00819780 |
추천 비교
추천 비교